Gyre Therapeutics, Inc. (GYRE)
Nasdaq · Healthcare · Biotechnology
$7.35+3.38%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $779M
- Forward P/E
- 122.5
- 52-week range
- $5.44 – $9.42
- 52-week change
- −2.20%
- EPS (trailing)
- −$0.26
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $117M (+10.24%)
- Net income
- $9.9M
- Operating margin
- 9.9%
- Diluted EPS
- $0.02
- Free cash flow
- −$180K
From the company’s annual report on SEC EDGAR.
About Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
Headquarters: San Diego, United States · 625 employees · gyretx.com